<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910912-0045</DOCNO><DOCID>910912-0045.</DOCID><HL>   Technology:   Sandoz Wins Europe Patent   For Genetics Stimulator</HL><DATE>09/12/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   GENI Z.SAN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)C)</IN><RE>EUROPE (EU)MASSACHUSETTS (MA)NORTH AMERICA (NME)SWITZERLAND (SZ)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   CAMBRIDGE, Mass. -- Genetics Institute Inc. said that itslicensee, Sandoz Ltd., received a European patent coveringGenetics' white blood cell stimulator GM-CSF.   The stimulator is a natural human protein, cloned byGenetics, that stimulates formation of white blood cells, thebody's defense against infection. Genetics and Sandoz areseeking marketing approval in the U.S. and Europe for GMCSFas a treatment for patients whose white blood cells have beendepleted during cancer therapy.</LP><TEXT>   &quot;The European patent is indicative of our expected,strong, world-wide intellectual property protection forGMCSF,&quot; said Bruce Eisen, vice president and chief patentcounsel. A similar patent application in the U.S. is understudy by the U.S. patent office because Immunex Corp.,Seattle, also has filed a patent claiming to cover GM-CSF.</TEXT></DOC>